Corinna T.
- Country
- Germany
- Department
- Frauenklinik
Research Overview
Data & Insights
Has run more than one trial at 0 of 33 partner sites.
Specializations
Gastrointestinal Oncology
Focuses on malignant diseases of the digestive tract, including advanced and metastatic forms of colorectal, gastric, esophagogastric junction, and cholangiocarcinoma.
- metastatic colorectal cancer
- KRAS G12C‑mutated colorectal adenocarcinoma
- locally advanced gastric cancer
- gastroesophageal junction adenocarcinoma
- cholangiocarcinoma with FGFR alterations
Emphasis on integrating targeted agents and immunotherapies.
Breast Oncology
Investigates both hormone‑receptor negative and lobular subtypes of breast cancer, with attention to high‑risk and early‑stage disease.
- triple‑negative breast cancer
- HER2‑negative breast cancer
- high‑risk lobular breast cancer
- neoadjuvant chemotherapy strategies
- adjuvant immunotherapy
Focus on improving event‑free and invasive disease‑free survival.
Gynecologic Oncology
Covers primary and advanced malignancies of the ovary, fallopian tube, peritoneum, and related high‑grade epithelial tumors.
- high‑grade serous ovarian cancer
- primary peritoneal carcinoma
- fallopian tube carcinoma
- platinum‑based chemotherapy combined with PARP inhibition
- biomarker‑driven treatment selection
Targets patients with FIGO stage III/IV disease.
Hematologic Malignancies
Engages with indolent and aggressive lymphoid cancers, emphasizing novel antibody‑based regimens.
- follicular lymphoma (FLIPI 2‑5)
- aggressive B‑cell lymphoma
- bispecific antibody therapies
- lenalidomide‑based combinations
- CD20‑directed immunotherapy
Aims to enhance progression‑free survival in treatment‑naïve patients.
Immuno‑oncology & Targeted Therapy
Integrates checkpoint inhibition, bispecific antibodies, and molecularly targeted agents across tumor types.
- PD‑L1 checkpoint blockade
- KRAS G12C inhibition
- FGFR‑directed therapy
- HER2‑targeted monoclonal antibodies
- immune‑preserving chemoradiation
Seeks synergistic effects between immunotherapy and conventional regimens.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.